Nature Biotechnology, Published online: 11 January 2021; doi:10.1038/s41587-020-00791-6
Following mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes.
Source: Nature Biotecnology